194 related articles for article (PubMed ID: 23216662)
1. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
Fujiki M; Aucejo F; Kim R
Clin Transplant; 2013; 27(2):169-77. PubMed ID: 23216662
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment after orthotopic liver transplantation: is it really necessary?
Kim R; Tan A; Estfan B; Aucejo F
Oncology (Williston Park); 2009 Dec; 23(14):1276-81. PubMed ID: 20120841
[TBL] [Abstract][Full Text] [Related]
3. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
4. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib use in the transplant setting.
Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation.
Xu J; Shen ZY; Chen XG; Zhang Q; Bian HJ; Zhu P; Xu HY; Song F; Yang XM; Mi L; Zhao QC; Tian R; Feng Q; Zhang SH; Li Y; Jiang JL; Li L; Yu XL; Zhang Z; Chen ZN
Hepatology; 2007 Feb; 45(2):269-76. PubMed ID: 17256759
[TBL] [Abstract][Full Text] [Related]
8. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Welker MW; Bechstein WO; Zeuzem S; Trojan J
Transpl Int; 2013 Feb; 26(2):109-18. PubMed ID: 22994652
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
10. How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Antoniou E; Mantas D; Paraskeva P; Dimitroulis D; Smyrnis A; Nikitakis N; Labadariou A; Tsavaris N; Vernicos P; Kostakis A
Transplant Proc; 2012 Nov; 44(9):2745-7. PubMed ID: 23146511
[TBL] [Abstract][Full Text] [Related]
11. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Chen K; Man K; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q
Liver Transpl; 2014 Mar; 20(3):261-9. PubMed ID: 24376158
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].
Zhang ZH; Ma LW; Song SB; Xiu DR; Wang JJ; Yang XX; Jia YM
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):45-7. PubMed ID: 15771799
[TBL] [Abstract][Full Text] [Related]
13. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Cabibbo G; Maida M; Cammà C; Craxì A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1355-61. PubMed ID: 24224926
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
[TBL] [Abstract][Full Text] [Related]
16. Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.
Zhang Q; Chen H; Li Q; Zang Y; Chen X; Zou W; Wang L; Shen ZY
Invest New Drugs; 2011 Dec; 29(6):1360-9. PubMed ID: 21809025
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
